跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,005 条关于
“VEGF-TKI”
全部
5,005
临床试验
3,364
药物
653
机构
29
资讯
959
2年前
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk Metastatic Renal Cell Carcinoma
5个月前
HiberCell's HC-7366 Shows Promise in Late-Line Renal Cell Carcinoma with 37% Response Rate in Phase 1b Trial
去年
FDA Accepts Resubmission of Rivoceranib and Camrelizumab for Liver Cancer
去年
Rivoceranib Plus Camrelizumab Shows Promise in First-Line HCC Treatment
去年
Tivozanib Monotherapy Shows Promise as Second-Line Treatment for Metastatic RCC Following Contemporary Immunotherapy
去年
China Approves MSD's Welireg (belzutifan) for VHL-Associated Tumors
去年
Ramucirumab Plus Osimertinib Extends PFS in EGFR-Mutated NSCLC
去年
China Approves MSD's Welireg (belzutifan) for VHL Disease-Associated Tumors
去年
FDA Accepts Rivoceranib and Camrelizumab Combination for Liver Cancer
去年
Belzutifan Monotherapy Shows Manageable Safety Profile in Renal Cell Carcinoma: Pooled Analysis
第 1 页,共 96 页
上一页
下一页